Orforglipron (orforglipron)
Lilly's once-daily non-peptide oral GLP-1. No food restrictions, easier to manufacture.
Orforglipron is Eli Lilly's investigational once-daily oral GLP-1 receptor agonist. Unlike Rybelsus, orforglipron is a small-molecule (non-peptide) drug — meaning it can be absorbed without complex food restrictions. FDA approval is expected in 2026.
Overview
Orforglipron is a small-molecule GLP-1 receptor agonist developed by Lilly. Because it is a non-peptide, it is not destroyed by stomach acid like semaglutide, eliminating the need for SNAC absorption enhancer or empty-stomach dosing. It is taken once daily without food restrictions.
How Orforglipron Works
Same mechanism as injectable GLP-1s — appetite suppression, slowed gastric emptying, glucose-dependent insulin, glucagon suppression. The advantage is convenience: a daily pill with no food timing requirements.
Dosing & Schedule
Phase 3 doses: 6, 12, 24, and 36 mg daily. The 36 mg dose produced ~14.7% weight loss in Phase 2.
Effectiveness — Trial Data
Phase 2 (36 weeks, 36 mg dose): 14.7% weight loss. Comparable to injectable semaglutide. ATTAIN Phase 3 results expected late 2025 / early 2026.
Side Effects
Standard GLP-1 GI profile (nausea, diarrhea, constipation). Possibly fewer than injectable GLP-1s due to smoother absorption curve. Long-term safety data still pending.
Cost — How Much Orforglipron Costs in 2026
Not yet on market. Pricing will be set at launch (expected 2026). Likely cheaper to manufacture than peptide drugs, which could translate to lower retail price over time.
Who Is Orforglipron For?
Once approved: adults with obesity and adults with type 2 diabetes preferring oral medication.
Orforglipron Alternatives
Available now: Rybelsus (oral peptide GLP-1), injectable semaglutide or tirzepatide.